A Study of Combivir Plus Abacavir Plus 141W94 in Patients Who Previously Have Used Anti-HIV Drugs

Completed · Not applicable

Conditions studied: HIV Infections

In brief

The purpose of this study is to test the effectiveness of Combivir plus abacavir plus 141W94 in patients who previously have used anti-HIV drugs.

Key facts

Study ID

NCT00002217

Run by

Glaxo Wellcome

Last updated by the study team

2005-06-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients must have:
• CD4 count greater than 50 cells/mm3.
• HIV RNA less than 50,000 copies/ml.
• No active AIDS (excluding CD4 count less than 200 cells/mm3).
• Ability to comply with dosing schedule and protocol evaluations.
• Prior Medication:
• Allowed:
• AZT or non-nucleoside reverse transcriptase inhibitors (NNRTIs).

You may not qualify if…

• Co-existing Condition:
• Patients with any of the following symptoms or conditions are excluded:
• Active AIDS (not excluding CD4 count less than 200).
• Malabsorption syndrome affecting drug absorption.
• Serious medical condition that would compromise safety of the patient.
• Concurrent Medication:
• Excluded:
• AZT or NNRTIs.
• More than 1 week treatment with any protease inhibitor.
• Enrollment in any other investigational drug protocol.
• Patients with the following prior conditions are excluded:
• History of clinically relevant pancreatitis or hepatitis within the past 6 months.
• Required:
• Antiretroviral therapy with either single or double reverse transcriptase inhibitors.

Where it is running

• Anderson Clinical Research — Pittsburgh, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.